结直肠癌进展过程中的共识分子亚型转换
该研究基于RNA表达谱的CMS分类,比较同一结直肠癌病变的前驱区和癌区的基因组与转录组数据。共纳入24例内镜下切除的T1-2期CRC患者,另对85例良性腺瘤进行CMS分型。结果显示良性腺瘤几乎均为CMS3(91.8%),前驱区以CMS2为主(66.7%),CMS4仅见于癌阶段,且CMS3前驱区多数发生亚型转换(7例中6例),其中4例转为CMS4。
要点
- 良性腺瘤几乎均为CMS3,前驱区以CMS2为主,CMS4仅见于癌阶段。
- CMS3前驱区多数发生亚型转换,常转为侵袭性更强的CMS4。
- CMS2特征在早期CRC发展中相对固定,亚型转换与TP53突变或克隆选择相关。
核心结论
- CMS3与惰性前驱病变相关,不易进展为CRC,进展时常伴亚型转换至CMS4。
- 获得的CMS2特征在早期CRC发展中相对固定。
- 亚型转换可伴随新驱动突变(TP53)或克隆选择性扩增,也可独立于遗传改变发生。
研究设计与样本
- 比较同一CRC病变前驱区与癌区的基因组和转录组数据。
- 纳入24例内镜下切除的T1-2期CRC患者。
- 对85例良性腺瘤进行CMS分型。
主要发现
- 良性腺瘤中91.8%为CMS3。
- 前驱区CMS2占66.7%,CMS3占29.2%,CMS4缺失。
- CMS4起源于癌阶段。
- CMS3前驱区7例中6例在癌区发生亚型转换,其中4例转为CMS4。
临床怎么用
- CMS3前驱病变可能提示较低进展风险,但进展时需警惕CMS4转换。
- CMS2特征在早期CRC中相对稳定,可作为分型参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The consensus molecular subtype (CMS) classification divides colorectal cancer (CRC) into four distinct subtypes based on RNA expression profiles. The biological differences between CMSs are already present in CRC precursor lesions, but not all CMSs pose the same risk of malignant transformation. To fully understand the path to malignant transformation and to determine whether CMS is a fixed entity during progression, genomic and transcriptomic data from two regions of the same CRC lesion were compared: the precursor region and the carcinoma region. In total, 24 patients who underwent endoscopic removal of T1-2 CRC were included. Regions were subtyped for CMS and DNA mutation analysis was performed. Additionally, a set of 85 benign adenomas was CMS-subtyped. This analysis revealed that almost all benign adenomas were classified as CMS3 (91.8%). In contrast, CMS2 was the most prevalent subtype in precursor regions (66.7%), followed by CMS3 (29.2%). CMS4 was absent in precursor lesions and originated at the carcinoma stage. Importantly, CMS switching occurred in a substantial number of cases and almost all (six out of seven) CMS3 precursor regions showed a shift to a different subtype in the carcinoma part of the lesion, which in four cases was classified as CMS4. In conclusion, our data indicate that CMS3 is related to a more indolent type of precursor lesion that less likely progresses to CRC and when this occurs, it is often associated with a subtype change that includes the more aggressive mesenchymal CMS4. In contrast, an acquired CMS2 signature appeared to be rather fixed during early CRC development. Combined, our data show that subtype changes occur during progression and that CMS3 switching is related to changes in the genomic background through acquisition of a novel driver mutation (TP53) or selective expansion of a clone, but also occurred independently of such genetic changes. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
引用
- van de Weerd S, Torang A, Zwager LW, et al. Consensus molecular subtype transition during progression of colorectal cancer. J Pathol. 2023. PMID: 37681286. doi:10.1002/path.6176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。